ENLV
Enlivex Ltd.
Healthcare · Biotechnology · NCM
HIGH
Data Confidence: 100.0%
Market Regime
Analysis pending
Today's Read
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-03
Full Daily Analysis
Key Metrics
How this company measures up on the fundamentals that matter
Market Cap
$176M
Total market value of the company
0.03
Very cheap relative to earnings
-0.94
Based on estimated future earnings — lower means cheaper
Rev Growth
0.0%
Year-over-year revenue change
Profit Margin
0.0%
How much profit the company keeps from each dollar of revenue
126.2%
Return on equity — how efficiently it uses shareholder money
Recommendation
N/A
Consensus view from ? analysts covering this stock
About Enlivex Ltd.
Company description not available.
Ethical Screening
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
0.4% PASS
Debt must be below 33% of total assets
Cash Ratio
3.3% PASS
Interest-bearing cash below 33% of assets
Receivables
0.0% PASS
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
MARKDOWN
Price trending down — defensive positioning
-0.093
Returns do not compensate for the risk — negative edge
-0.0840
No positive edge detected — the data suggests staying out
-0.472
Drawdown risk outweighs the returns — higher risk profile
Annual Return
-29.8%
Historical annualised return based on price data
-63.1%
Largest peak-to-trough decline — the worst it has been
BEAR
Statistical model detects bearish conditions
Days in State
10
How long the current regime has persisted — longer means more stable
Market Data
Trading characteristics and market positioning
Avg Volume
N/A
Average daily shares traded — higher means easier to buy and sell
N/A
Days it would take all short sellers to cover — higher means more crowded
0.0%
Annual dividend as a percentage of the share price
$25.48
Earnings per share over the last 12 months
Financial Health
Balance sheet strength and cash generation — the foundation of long-term value
0.03
Conservative use of debt — low financial risk
Quick Ratio
N/A
Like current ratio but excludes inventory — stricter test
Gross Margin
N/A
Revenue left after cost of goods — higher means pricing power
Operating Margin
N/A
Profit from core operations before interest and tax
N/A
Negative — the business is spending more than it generates
Revenue (TTM)
N/A
Total revenue over the last 12 months
Net Income
N/A
Loss-making — spending exceeds revenue after all costs
What If You'd Bought ENLV?
| Period |
Price Then |
Price Return |
Divs/Share |
$1,000 Became |
Total Return |
| 1 Month |
$0.74 |
-10.0% |
— |
$900 |
-10.0% |
| 2 Months |
$0.96 |
-30.5% |
— |
$695 |
-30.5% |
| 3 Months |
$1.07 |
-37.5% |
— |
$625 |
-37.5% |
| 6 Months |
$0.96 |
-30.3% |
— |
$697 |
-30.3% |
| 1 Year |
$0.96 |
-30.3% |
— |
$697 |
-30.3% |
| 2 Years |
$1.36 |
-50.8% |
— |
$492 |
-50.8% |
| 3 Years |
$2.68 |
-75.0% |
— |
$250 |
-75.0% |
| 5 Years |
$9.55 |
-93.0% |
— |
$70 |
-93.0% |
Historical returns. Past performance does not guarantee future results. Prices from market close data.
Framework Review History
Timestamped framework reads — tracking how the analysis evolves over time
2026-07-03
MARKDOWN $0.71
+0.0% Review #2
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02
MARKDOWN $0.71
Review #1
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows negative risk-adjusted returns.
Latest Analysis — ENLV
Timestamped intelligence from our daily research pipeline
Want deeper analysis on Enlivex Ltd.?
Our framework analyses ENLV daily across 19 analytical perspectives — positioning, macro, sentiment, volatility, options, sector rotation, and more. Members get the read 24 hours before anyone else.
Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-22